Tetracycline antimicrobials are bacteriostatic agents that act by binding to the bacterial 30S ribosomal subunit to inhibit protein synthesis. These agents have broadspectrum activity and have been used for the treatment of various microbial infections including those caused by anaerobic bacteria, Chlamydophila (Chlamydia) spp, and Rickettsia spp. Minocycline is a second-generation antimicrobial of the tetracycline group and has greater lipophilicity and antimicrobial activity than other tetracycline agents.1,2 The excellent lipid solubility of minocycline leads to good distribution in various tissues throughout the body, including penetration of the blood-brain and blood-ocular barriers.3 In dogs, rats, and humans, tissue concentrations of minocycline are generally higher than their serum concentrations.3–5
Minocycline is more active against gram-positive bacteria than gram-negative bacteria.6 Gram-positive bacteria of particular relevance include tetracycline-resistant strains or methicillin-resistant strains of Staphylococcus aureus, and pharmacokineticpharmacodynamic models for activity against S aureus have been reported.2,7 A study5 involving humans revealed minocycline is rapidly and completely absorbed after oral administration and has a prolonged biological half-life of approximately 16 hours. The long half-life allows minocycline to be used effectively to treat infections with administration of 1 or 2 doses/d.
In horses, minocycline may be used when other antimicrobials, such as gentamicin or cephalothin, have failed. This drug is commonly administered at the recommended human dosage (2.2 mg/kg, IV, q 12 h or q 24 h) in horses, but the effect of this dosage has not been evaluated in horses. Tetracyclines are known to cause serious adverse reactions that consist mainly of cardiovascular depression or hypotension in dogs, ruminants, and horses.8–12 For the effective and safe use of antimicrobials, it is important to evaluate their pharmacokinetic and tissue distribution in the target species. Pharmacokinetic data on minocycline are available for dogs,1,8 ruminants,13,14 rabbits,15 and humans.5,16,17 In horses, the pharmacokinetics and tissue distribution of doxycycline, which has a similar structure and bacteriologic properties to minocycline, have been reported18–20 but there is no comparable pharmacokinetic information for minocycline. The purpose of the study reported here was to determine the pharmacokinetics and tissue localization of minocycline in mares after a single IV injection.
Area under the plasma concentration vs time curve from 0 to infinity
Area under the first moment curve from 0 to infinity
Minimal inhibitory concentration
Mean residence time
Reverse-phase high-performance liquid chromatography
Apparent volume of distribution based on area under the curve
Apparent volume of distribution at steady state
Minopen, Sawai Pharmaceutical Co, Yodogawa, Osaka, Japan.
Ravonal, Mitsubishi Tanabe Pharma Co, Osaka, Japan.
Relaxin injection, Kyorin Pharmaceutical Co, Tokyo, Japan.
Domitor, Nippon Zenyaku Kogyo Co, Fukushima, Japan.
Demeclocycline hydrochloride, Sigma-Aldrich Co, St Louis, Mo.
Polytron-aggregate, Kinematica Inc, Littau-Lucerne, Switzerland.
Oasis HLB extraction cartridge, Waters Co, Milford, Mass.
Prominence, Shimadzu Co, Tokyo, Japan.
Nonafluoropentanoic acid, Sigma-Aldrich Co, St Louis, Mo.
COSMOSIL 5C18-MS-2, Nacalai Tesque Inc, Kyoto, Japan.
Minocycline hydrochloride, Sigma-Aldrich Co, St Louis, Mo.
SAAM- II program, University of Washington, Seattle, Wash.
Barza M, Brown RB, Shanks C, et al. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975; 8:713–720.
Steigbigel NH, Reed CW, Finland M. Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro. Am J Med Sci 1968; 255:179–195.
Kelly RG, Kanegis LA. Metabolism and tissue distribution of radioisotopically labeled minocycline. Toxicol Appl Pharmacol 1967;11:171–183.
Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791:337–343.
Macdonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973; 14:852–861.
Ensink JM, van Klingeren B, Houwers DJ, et al. In-vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands. Equine Vet J 1993;25:309–313.
Karen EB, Alan RN, Alasdair PM. Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2008; 52:4370–4373.
Wilson RC, Kitzman JV, Kemp DT, et al. Compartmental and noncompartmental pharmacokinetic analyses of minocycline hydrochloride in the dog. Am J Vet Res 1985; 46:1316–1318.
Gyrd-Hansen N, Rasmussen F, Smith M. Cardiovascular effects of intravenous administration of tetracycline in cattle. J Vet Pharmacol Ther 1981; 4:15–25.
Potter WL. Collapse following intravenous administration of oxytetracycline in two horses. Aust Vet J 1973; 49:547–548.
Riond JL, Riviere JE, Duckett WM, et al. Cardiovascular effects and fatalities associated with intravenous administration of doxycycline to horses and ponies. Equine Vet J 1992; 24:41–45.
Riond JL, Duckett WM, Riviere JE, et al. Concerned about intravenous use of doxycycline in horses (lett). J Am Vet Med Assoc 1989; 195:846–848.
Ziv G, Sulman FG. Analysis of pharmacokinetic properties of nine tetracycline analogues in dairy cows and ewes. Am J Vet Res 1974; 35:1197–1201.
Wilson RC, Green NK. Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. Am J Vet Res 1986; 47:650–652.
Nicolau DP, Freeman CD, Nightingale CH, et al. Pharmacokinetics of minocycline and vancomycin in rabbits. Lab Anim Sci 1993; 43:222–225.
Yamamoto T, Takano K, Matsuyama N, et al. Pharmacokinetic characteristics of minocycline in debilitated elderly patients. Am J Ther 1999; 6:157–160.
Savin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15:355–366.
Davis JL, Salmon JH, Papich MG. Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses. Am J Vet Res 2006; 67:310–316.
Womble A, Giguère S, Lee EA. Pharmacokinetics of oral doxycycline and concentrations in body fluids and bronchoalveolar cells of foals. J Vet Pharmacol Ther 2007; 30:187–193.
Gilmour MA, Clarke CR, Macallister CG, et al. Ocular penetration of oral doxycycline in the horse. Vet Ophthalmol 2005; 8:331–335.